key: cord-0906268-82j5m39j authors: Quartuccio, Luca; Valent, Francesca; Pasut, Enrico; Tascini, Carlo; Vita, Salvatore De title: Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy date: 2020-05-20 journal: Joint Bone Spine DOI: 10.1016/j.jbspin.2020.05.003 sha: 0357d5d97be31c0f818aec9efaa21d1e2176b9b9 doc_id: 906268 cord_uid: 82j5m39j Abstract Objective: The aim of this study is to determine the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) among adult patients treated with biologic agents or small molecules for chronic inflammatory rheumatic diseases, in particular chronic inflammatory arthritides. Methods: To this end, a population-based study, in the province of Udine (466,700 inhabitants, with age > 15 years old, Friuli Venezia Giulia region, Italy) was planned. The primary outcome was the prevalence of COVID-19 in the first two months of the outbreak. All the rheumatic patients treated with biologic agents or small molecules in the last 6 months in our province were included (N=1051). Results: From February 29 to April 25, 2020, 4 adult patients (4/1051, i.e. 3.8/1000, 95% Confidence Interval 1.5-9.7/1000) were registered as swab test positive by PCR for COVID-19. Overall, a total of 47/1051 (4,5%) cases were tested for COVID-19 by PCR in the same period, and 15 of them due to symptoms compatible with COVID-19. In the general population, the prevalence was 937 cases/466700 (2/1000, 95% Confidence Interval 1.9-2.1/1000, p value=0.33, chi square test), and 20,179/466,700 (4.3%) swab tests for COVID-19 were performed.. Conclusion: The risk of COVID-19 in rheumatic patients under biologic agents or small molecules does not appear different from that observed in the general population. Patients should be informed to safely proceed with their treatment and follow the rules for self-protection to COVID-19. The ongoing outbreak by novel coronavirus has been defined as a global public health emergency by World Health Organization (WHO) [1] . COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main way of transmission. Currently, the research on COVID-19 is growing at great speed. Italy is one of the country showing the highest rate of mortality in the world, mainly in the northern regions [2] . While pre-existing pulmonary and cardiovascular disease as well as diabetes mellitus are known risk factors for the worst outcome for COVID-19 [3] , the impact of chronic rheumatic diseases, and, in particular, if the risk of COVID-19 while using a biologic agent (b-DMARD) or a small molecule (ts-DMARD) for chronic inflammatory arthritis is higher than in the general population, is still unknown [1] . Biologic agents increase the risk for infections, although the advantages largely overcome that risk [4] . Moreover, the most severe complication of COVID-19 pneumonia seem to be caused by a cytokine storm syndrome [5] as an exaggerated response of the immune system to the virus [4, 6] for whom many rheumatic drugs, including biologic agents, are currently under investigations [7, 8] . Prevalence data in patients with chronic inflammatory rheumatic diseases treated with b-DMARDs or ts-DMARDs and their risk of COVID-19 are still scarce, and limited to case series [9] [10] [11] . Those preliminary data may be reassuring for clinicians, but, importantly, they lack of comparison to the reference population. Therefore, the aim of this study is to compare the prevalence of COVID-19 in this population of patients with the general population in order to provide a stronger evidence supporting the management of patients with inflammatory rheumatic diseases during COVID-19 outbreak [12] . The primary objective of the present study is to define the prevalence and the severity of COVID-19 in a population of patients suffering from a chronic inflammatory rheumatic disease under treatment with a biologic agent or a small molecule during the first two months of COVID-19 outbreak. The cases were all the adult patients with a rheumatic disease and who were under treatment with a b-or a ts-DMARD from September 2019 to April 2020 in the province of Udine, Italy. A computer database from the Pharmacy service of the province of Udine recording past and present treatments with b/ts-DMARDs in the same cases was used. All the clinical charts of these cases were revised to verify they were proceeding with treatment at the last contact. The prevalence of COVID-19 during the month of March 2020 and April 2020 was compared to that of the general population in the province of Udine after excluding subjects ≤ 15 years old (a total of 466,700 inhabitants), the first COVID-19 case in this province being reported on February 29, 2020. Importantly, in our region, all the patients who undergo a biologic or small molecule treatment must be evaluated by a public consultant rheumatologist every six months for renewing and proceeding with their own therapeutic plan and then they need to be registered by the Pharmacy service that supplies the drug about every two months until to the treatment plan expiration. Diagnostic tests for COVID-19 were conducted in accordance with the indication provided by the Italian Ministry of Health, following the rules suggested by the WHO, in symptomatic subjects. For initial diagnostic testing for COVID-19, the Italian Ministry of Health recommends collecting and testing an upper respiratory specimen. A nasopharyngeal specimen is the preferred choice for swabbased COVID-19 testing. All the people of the province of Udine, and in particular, all the rheumatic patients treated with b/ts-DMARDS, as well as other patients treated with immunosuppressive or cytotoxic agents for other diseases, were informed by national and local media to contact their own general practitioner (GP) in case of symptoms such as body temperature over 37.4°C, cough, or dyspnoea. In turn, the GP sent the patients to undergo testing for COVID-19, whenever this infection was suspected. Variables were expressed as mean±standard deviation or frequency, as appropriate. Comparison between study population and general reference population was performed by chi square test. P value <0.05 was considered significant. The study was conducted in accordance with the ethical principles of the Helsinki Declaration, and approved by the local Ethics Committee. Within the province of Udine, 1053 patients taking biologic drugs or small molecules were identified. Of them, two patients were excluded since they suspended the drug after a diagnosis of cancer. They were 703 (66.9%) women and 348 (33.1%) men, with a mean age of 58.4±14.6 years. In order to provide background information on our study population, complete data on the underlying rheumatic disease were available for 925/1051 (88%). The diagnoses were: rheumatoid arthritis They were two females and two males, aged from 42 to 69 years, three affected by seronegative spondyloarthritis and one by rheumatoid arthritis (table 1). The disease duration is longer than one year in all of them and the exposure to biologic drugs or small molecules along the clinical history of those patients ranged from 12 to 72 months. Other concomitant treatments for the rheumatic disease including methotrexate and low-dose of prednisone in two of them. Three out of four presented preexisting comorbidities including active pulmonary or cardiovascular diseases. Characteristics of the COVID-19 infection are reported in table 2. Briefly, three patients required hospital admission and two of them needed oxygen support, but none was subsequently transferred to ICU. All but one of the patients received antiviral drugs and one also with hydroxychloroquine. All patients showed a favorable outcome. Laboratory features of the three hospitalized patients were reported in table 3. To our knowledge, this is the first report comparing the COVID-19 incidence among patients suffering from chronic inflammatory diseases under ongoing treatment with a biologic agent or a small molecule with the general population. The incidence of 3.8/1000 (95% Confidence Interval 1.5-9.7/1000) is not different from that estimated in the reference general population. On the contrary, b-DMARDs and ts-DMARDs put patients at significantly higher risk of infections [6] , especially in the respiratory tract, than the general population. Therefore, our result is reassuring for clinicians, and, thus, b-or ts-DMARDs in rheumatic diseases could neither substantially increase the risk of COVID-19, nor worsen the course of COVID-19, when it occurs. This observation is consistent with previous findings during the previous outbreaks, such as SARS and Middle East respiratory syndrome, regarding favorable outcome in immunosuppressed patients for organ transplantation, cancer or autoimmune diseases [14] [15] [16] . Even if the true rate of COVID-19 is not known either in the general population or among rheumatic patients, rheumatic patients under immunosuppressors are usually more prone to alert clinicians in the case of symptoms of infection, and to protect themselves earlier from possible contagion. The number of patients, who were tested for COVID-19 (4.5%) was similar to the reference population (4.3%). However, among rheumatic patients tested for COVID-19, only one third (15/47, 31.9%) referred to healthcare providers for symptoms compatible with COVID-19, thus underlying a possible social behavior of patients with rheumatic disease (i.e., being more careful in social contacts because of their immunosuppression) that likely played an important role in infection rate and control. This feature needs appropriate studies. Overall, it is an important observation, though it needs to be confirmed by other groups, since this is a large population of chronic immunosuppressed patients, and, among the different subgroups of rheumatic patients, they probably represent those at highest risk for infectious complications both for their own clinical characteristics (age, comorbidity, moderate to severe inflammatory chronic rheumatic disease) and related treatments (chronic glucocorticosteroids, b-or ts-DMARD, long disease duration, combination of two immunosuppressors), as already known [17] . We limited our analysis to rheumatic diseases that 8 biologics are at greater infectious risk than the others. Previous epidemiologic data also in our region of Italy supported this notion [18] . The possible mitigation of symptoms by biologic agents or small molecules cannot be excluded, thus causing an underestimation of COVID-19 in our study population. Finally, the weight of antimalarials in possibly decreasing the prevalence of COVID-19 in our study population was negligible (<10%). However, antimalarials failed to reduce mortality in critically ill COVID-19 patients in a recent randomized controlled trial [19] , and further studies are warranted [20] . Yet, more than 50% of our patients have been in treatment with an anti-TNF agent (adalimumab and etanercept, in particular), therefore, our conclusions are more properly applicable in patients with chronic inflammatory arthritides who are taking an anti-TNF agent. Finally, regarding our four patients positive for COVID-19, the infectious disease was generally characterized by a favorable outcome, in line with the recently reported case series [9] [10] [11] . To conclude, the risk of COVID-19 in chronically immunosuppressed rheumatic patients under biologics or small molecules does not appear higher than the general population, in particular for those patients with chronic inflammatory arthritides taking an anti-TNF agent. Overall, the outcome of the infection might be favorable. Thus, patients should be informed to safely proceed with their treatments during the outbreak, and to strictly adhere to the principles for self-protection to COVID- Local patients' associations for rheumatic diseases and general practitioners were involved in the identifying this topic as an urgent need for the best management of immunosuppressive treatments, and in particular biologic agents or small molecules, in this outbreak. This research received no external funding. The study was conducted in accordance with the ethical principles of the Helsinki Declaration. Written patients' consents for using data for research purpose were obtained at the time of hospital admission, and the local Ethics Committee approved the study. The data that support the findings of this study are available on request from the corresponding author, [LQ] . A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence Estimation of COVID-19 outbreak size in Italy Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis COVID-19: consider cytokine storm syndromes and immunosuppression EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Old and new antirheumatic drugs for the treatment of COVID-19 Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome Covid-19 in Immune-Mediated Inflammatory Diseases -Case Series from New York Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases World Health Organization. Laboratory testing for coronavirus disease suspected human cases: interim guidance Coronaviruses and immunosuppressed patients. The facts during the third epidemic COVID-19 infection: the perspectives on immune responses Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) No conflicts of interest are disclosed for all the authors. LQ designed data collection tools, monitored data collection for the whole study, wrote the statistical analysis plan, cleaned and analysed the data, and drafted and revised the paper. He is guarantor.FV and SDV implemented the statistical analysis, analysed the data, and drafted and revised the paper. EP, CT analysed the data and drafted and revised the paper.